Meta‑analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S‑1 plus cisplatin (SP) as first‑line treatment for advanced gastric cancer

Phase I dose‑escalation study on irinotecan, cisplatin, and S‑1 combination in chemotherapy‑naïve patients with HER2‑negative advanced gastric cancer (HERBIS‑4B, OGSG 1106)

Effect of the number of cycles of docetaxel + S‑1 therapy on long‑term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials

TRESBIEN (OGSG 2101) Encorafenib, binimetinib and cetuximab for early recurrent Stage II/III BRAF V600E-mutated CRC

Histology classification highlights the difference in the effectiveness of S-1 over capecitabine when combined with cisplatin in patients with HER2-negative unresectable advanced or recurrent gastric cancer with measurable disease

Efficacy of SP and XP for HER2-negative unresectable advanced recurrent gastric cancer varies by histologic type

進行胃癌一次治療におけるSP対XPの無作為化試験のメタ解析

Efficacy of SP and XP for HER2-negative unresectable advanced recurrent gastric cancer varies by histologic type

Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy OGSG1201

Stage II/III大腸癌根治切除後の補助化学療法中または治療後に再発したRAS野生型かつBRAF V600E変異型の早期再発大腸癌患者に対するエンコラフェニブ+ビニメチニブ+セツキシマブ療法の有効性と安全性を探索する第II相試験 (TRESBIEN/OGSG2101)